EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti‐CD30 ( Ber‐H2 ) epitope requires structural elements as shown by mass spectroscopy and dual‐site associated kinetics

Phillip Daniel Warren iD, Margaret Helfrich Smith

Journal of Molecular Recognition · 2023

DOI: 10.1002/jmr.3011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Recognition, 2023. Verfasst von Phillip Daniel Warren und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ventana Medical Systems, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Ki-1 Antigen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Ber‐H2 mouse monoclonal antibody has been in use for 35 years for detecting the CD‐30 biomarker in a variety of lymphomas. Despite the wide use of this clone, we have not been successful in applying synthetic peptides derived from the published epitope sequence and affinity data toward the development of a new Ber‐H2‐based in vitro diagnostic reagent assay. We found that synthetic peptides based on the published epitope sequence do not function to inhibit antibody‐binding activity, thus indicating that the sequence is not the full epitope recognized by Ber‐H2. In this report, we used mass spectroscopic analysis of proteolyzed CD30 fragments capable of binding Ber‐H2 to identify additional regions within the epitope that participate in binding. Using surface plasmon resonance binding kinetic analyses and immuno‐histochemical peptide‐inhibition assays, we also demonstrate that the epitope sequence as originally reported is missing two key elements necessary for binding the Ber‐H2 antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalKi-1 AntigenAnimalsMiceEpitopesPeptidesMass SpectrometryEpitope MappingKinetics

Stichwörter der Autor:innen

Ber-H2 cloneCD30epitope mappingimmunohistochemistrysurface plasmon resonance

Substanzen

EpitopesAntibodies, MonoclonalKi-1 AntigenPeptides

Autor:innen und Institutionen

  • Ventana Medical Systems, Tucson, Arizona, USA.

ORCID-Profile: Phillip Daniel Warren

Förderung

  • Roche Diagnostics

Zitieren

APA

Warren, P. D., & Smith, M. H. (2023). Anti‐CD30 ( Ber‐H2 ) epitope requires structural elements as shown by mass spectroscopy and dual‐site associated kinetics. Journal of Molecular Recognition. https://doi.org/10.1002/jmr.3011

Vancouver

Warren PD, Smith MH. Anti‐CD30 ( Ber‐H2 ) epitope requires structural elements as shown by mass spectroscopy and dual‐site associated kinetics. Journal of Molecular Recognition. 2023. doi:10.1002/jmr.3011

BibTeX
@article{Warren2023,
  author = {Warren, Phillip Daniel and Smith, Margaret Helfrich},
  title = {Anti‐CD30 ( Ber‐H2 ) epitope requires structural elements as shown by mass spectroscopy and dual‐site associated kinetics},
  journal = {Journal of Molecular Recognition},
  year = {2023},
  doi = {10.1002/jmr.3011}
}
Kostenlos starten →